These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25927597)

  • 1. Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
    Kapoor S; Rodriguez D; Riwanto M; Edenhofer I; Segerer S; Mitchell K; Wüthrich RP
    PLoS One; 2015; 10(4):e0125603. PubMed ID: 25927597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
    Rodriguez D; Kapoor S; Edenhofer I; Segerer S; Riwanto M; Kipar A; Yang M; Mei C; Wüthrich RP
    Kidney Blood Press Res; 2015; 40(6):638-47. PubMed ID: 26698317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
    Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
    Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
    PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease.
    Riwanto M; Kapoor S; Rodriguez D; Edenhofer I; Segerer S; Wüthrich RP
    PLoS One; 2016; 11(1):e0146654. PubMed ID: 26752072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased water intake decreases progression of polycystic kidney disease in the PCK rat.
    Nagao S; Nishii K; Katsuyama M; Kurahashi H; Marunouchi T; Takahashi H; Wallace DP
    J Am Soc Nephrol; 2006 Aug; 17(8):2220-7. PubMed ID: 16807403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.
    Tonum K; Srimai N; Chabang N; Fongsupa S; Tuchinda P; Torres JA; Weimbs T; Soodvilai S
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
    Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
    Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
    J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
    Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Exercise Protects against the Progression of Renal Cyst Growth and Dysfunction in Rats with Polycystic Kidney Disease.
    Qiu J; Sato Y; Xu L; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2021 Dec; 53(12):2485-2494. PubMed ID: 34310502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential protective effects of Dapagliflozin in gentamicin induced nephrotoxicity rat model via modulation of apoptosis associated miRNAs.
    Mohamed DI; Khairy E; Saad SST; Habib EK; Hamouda MA
    Gene; 2019 Jul; 707():198-204. PubMed ID: 31075409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.